Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review summarizes proposed pathophysiological mechanisms of postpartum depression, highlighting neuroendocrine and neurobiological changes, but reports no new findings and calls for integrated understanding of the disorder.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This review discusses recent strategies targeting the neuroactive steroid biosynthetic pathway to enhance neurosteroidogenesis, highlighting their potential benefits for neurodegenerative and neuropsychiatric diseases, but reports no new clinical findings.

In this study, researchers found that in late pregnancy, the neuroactive progesterone metabolite allopregnanolone inhibits HPA axis responses to immune challenges via an opioid-mediated mechanism.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This review discusses the essential roles and complex regulation of PP2A in various physiological processes and reports no clinical results; the authors highlight the need for further mouse model research to explore PP2A's therapeutic potential.

This review proposes focusing on relationships between neuroactive steroids and psychiatric disorder symptoms, rather than relying on traditional disorder classifications, and reports no new clinical findings.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This review summarizes the role of neurosteroids in seizure disorders and highlights the potential of neurosteroid replacement therapy in epilepsy but presents no new clinical findings.

In this study, finasteride dose-dependently inhibited stress-induced increases in allopregnanolone in rats, while enhancing 20alpha-reduction of progesterone without affecting 3alpha-dihydroprogesterone or 11-deoxycorticosterone levels.

This study suggests that cerebrospinal fluid levels of the neurosteroids allopregnanolone and pregnanolone correlate negatively with PTSD and negative mood symptoms, with potential sex-specific differences in synthesis enzyme blocks.

This study found that midazolam improved PTSD-associated behavioral deficits in rats through its action on the TSPO, CBR, and neurosteroidogenesis pathways.

This paper reviews guidelines discussed at a meeting about research and practice themes, but reports no new research findings.

This study found that acute finasteride treatment decreased ethanol intake in male C57BL/6J mice, whereas chronic treatment showed diminished effects, implying compensatory changes in neurosteroid modulation.

This review discusses the potential therapeutic effects of targeting the endocannabinoid system for chemotherapy-induced peripheral neuropathy and reports no new clinical results, highlighting the need for ongoing research.

This study found no evidence of androgen deficiency or decreased peripheral androgen action in men with persistent sexual symptoms after finasteride use, but identified links to depressed mood and abnormal brain function.

This study found that progesterone pretreatment in rats potentiated the effect of ethanol on mesocortical dopamine levels, suggesting an influence of neuroactive steroids on ethanol's action.

This study suggests that 5α-reduced glucocorticoids may have anti-inflammatory potential and could serve as biomarkers for liver inflammation in metabolic disease, with implications for drug development.

This review focuses on neuroactive steroids' influence on GABA-ergic signaling and discusses challenges in developing them for various therapeutic uses, citing recent excitement from FDA approval of allopregnanolone for postpartum depression but reporting no new results.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

The authors describe drug repurposing as a promising strategy for finding new uses for existing drugs, noting it is efficient, cost-effective, and poses lower risks than traditional drug discovery processes, potentially aiding in the treatment of rare and difficult-to-treat diseases.

This article reviews behavioral dermatology, highlighting the importance of integrating physiological, social, and environmental factors in managing dermatologic conditions with behavioral components, but reports no new clinical results.

In this study, socially defeated mice showed increased alcohol consumption, and CRF-R1 antagonism selectively reduced drinking in these mice, suggesting a potential treatment target for stress-related alcohol use disorders.

This review highlights that children with adrenal disorders may experience neurological and psychiatric symptoms, with potential long-term cognitive and behavioral effects from excess glucocorticoids.

This study discusses levetiracetam's role as an alternative treatment for idiopathic generalized epilepsies, highlighting its potential effectiveness, especially for patients unsuitable for valproate.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.